Dong-A St (170900.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7170900005
Dong-A St financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 697.87 bn KRW | 808.78 bn KRW |
| Gross profit | 340.20 bn KRW | 361.10 bn KRW |
| Operating income | -25.00 bn KRW | 623.19 m KRW |
| EBIT | -153.44 m KRW | -20.24 bn KRW |
| Net income | -1.22 bn KRW | -28.59 bn KRW |
| Diluted EPS – continuing operations | -133.41 KRW | -2,971.77 KRW |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome; Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab/ Stillen 2X tab. to treat gastritis; Suganon tab./Sugamet XR tab. and Sugadapa tab./Sugatree XR tab for type 2 diabetes mellitus; DA-3880 PFS to treat renal anemia and darbepoetin-alfa; and Zydena tab. for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
More stocks
- Zhejiang Power New Energy Co. Ltd. A (688184.SS)
- Zhejiang Renzhi Co Ltd (002629.SZ)
- Kisco Holdings (001940.KS)
- EVgo Inc. (EVGO)
- Suncrete, Inc. Class A Common Stock (RMIX)
- Horizon Technology Finance Corp (HRZN)
- Yeal Electric Co.Ltd (300923.SZ)
- Ascom Holding AG (ASCN.SW)
- Alfen N.V. (703.DE)
- ORASURE TECHNOLOGIES INC (OSUR)
- Martifer SGPS S.A (MAR.LS)
- Khgears International Limited (4571.TW)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.